Clinical Trial Phase III to Assess the Non-inferiority of Dalap Duo® Product Compared to Epiduo® in the Treatment of Acne Vulgaris

NCT02716090 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2017-02-15

No results posted yet for this study

Summary
Conditions
Interventions
Sponsors
Investigators
Design
Eligibility
Timeline
Countries
Locations
Related
Entities

Summary

This study evaluates the non-inferiority of the product Dalap Duo® compared to Epiduo® medicine to treat acne. Half of the participants will receive Dalap Duo®, while the other half will receive Epiduo®.

Conditions

Acne Vulgaris

Interventions

DRUG: Adapalene and Benzoyl peroxide Dalap Duo®
DRUG: Adapalene and Benzoyl peroxide Epiduo®

Sponsors & Collaborators

Ache Laboratorios Farmaceuticos S.A.
lead INDUSTRY

Study Design

Allocation: RANDOMIZED
Purpose: TREATMENT
Masking: NONE
Model: PARALLEL

Eligibility

Min Age: 12 Years
Sex: ALL
Healthy Volunteers: No

Timeline & Regulatory

Primary Completion: 2015-11-30

Summary

Conditions

Interventions

Sponsors & Collaborators

Study Design

Eligibility

Timeline & Regulatory

Related Clinical Trials

Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% to Epiduo® and Both to a Placebo Control in the Treatment of Acne Vulgaris

A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris

Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris

Long-term Study of Epiduo in Patients With Moderate to Severe Acne

Evaluate Effectiveness of Epiduo® Gel in Reducing Antibiotic Sensitive & Resistant Strains of Propionibacterium (P)Acnes

More Related Trials